Skip to main content
. 2018 Jun 21;10(7):210. doi: 10.3390/cancers10070210

Figure 1.

Figure 1

Bar graphs showing percentage of tumors harboring somatic mutations of 6 major signaling pathways (NF-κB, PI3K, JAK/STAT, MAPK, NOTCH, WNT), and of the MHC Class I, and MHC Class II genes in (a) EBV(+) NPC cohort (n = 111), (b) HPV(+) HNSCC cohort (n = 36; TCGA) and (c) HPV(−) oropharyngeal cancer cohort (n = 11; TCGA). The NF-κB pathway is defined as TAB1/2/3, MAP3K7/14, CHUK, IKBKB, IKBKG, NFKBIA, NFKBIE, REL, RELA/B, NFKB1/2, LTBR, TNF, TNFAIP3, TNFSF11/13B, TNFRSF1A/8/11A/13C, BTRC, CYLD, NLRC5, TRADD, CD40, CD40LG, LTA, TRAF2/3/5/6, IL1B and IL1R1. The PI3K pathway is defined as AKT1/2/3, PIK3CA/B/D/G/2A/2B/2G, PIK3AP1, PIK3IP1, PDK1, MTOR, TSC1, TSC2, PTEN, RICTOR, RPTOR, RHEB and PIK3R1/2/3/4/5/6. The JAK/STAT pathway is defined as JAK1/2/3, STAT1/2/3/4/5A/5B/6, PTPN11, IL6, IL6R, IL6ST and SOCS3. The MAPK pathway is defined as SHC1/2/3, GRB2, H/N/KRAS, A/BRAF, RAF1, MAP2K1/2, MAPK1/3, RPS6KA1 and DUSP1/2/3/4/5/6/7/9. The NOTCH pathway is defined as DLL1/3/4, JAG1/2, NOTCH1/2/3/4, NUMB, DTX1/3L, NEDD4, MAML1, RBPJ, POFUT1, HES1/5 and HEY1/2/L. The WNT pathway is defined as WNT1/3A/5A/5B/7A, CTNNB1, HNF1A, FZD1/2/3/7/8/9/10, AXIN1, LEF1, LOXL2, DVL2/3, NKD1/2, TAB1/2, GSK3B, CSNK1A1, NLK and LRP5/6. The MHC Class I genes are defined as HLA-A/B/C/E/F/G/H/K/L/J, B2M and NLRC5. The MHC Class II genes are defined as HLA-DMA/B, HLA-DOA/B, HLA-DPA1/A2/B1/B2, HLA-DQA1/A2/B1/B2/B3 and HLA-DRA/B1/B2/B3/B4/B5/B9.